🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11529390

PCSK9 inhibitory polypolypeptides and methods of use

INSTITUT DE CARDIOLOGIE DE MONTREAL · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11530236

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11529347

SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11524962

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase

Prelude Therapeutics, Incorporated · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518750

3-methylideneoxan-4-one compounds and substituted derivatives thereof as inhibitors of tel

Northwestern University · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518772

Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors

NIKANG THERAPEUTICS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505600

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504390

Treatment of increased lipid levels with sterol regulatory element binding transcription f

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504364

Inhibitors of fibroblast activation protein

PRAXIS BIOTECH LLC · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497781

Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovi

CG ONCOLOGY, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498905

Inhibitors of platelet function and methods for use of the same

The Regents of the University of California · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498928

Macrocyclic spiroethers as Mcl-1 inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497734

Dual inhibitors of TIM-3 and PD-1 pathways

Aurigene Discovery Technologies Limited · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497740

Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy r

The Board of Regents of the University of Texas System · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492349

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11492351

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485738

Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485739

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485760

Inhibitors of CRISPR-Cas9

The Regents of the University of California · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485788

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479551

MTA-cooperative PRMT5 inhibitors

Mirati Therapeutics, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479543

Heterocyclic RIP1 kinase inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479770

Use of p38 inhibitors to reduce expression of DUX4

Fulcrum Therapeutics, Inc. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted